The procedure was performed percutaneously under DSA and ICE guidance. Post-procedure ultrasound confirmed the bioabsorbable PFO occluder had good morphology and position, complete closure with no residual shunt, no pericardial effusion, and no adverse reactions before or after closure, indicating successful closure.

We are honored to announce that HANGZHOU MEDTOURCHINA TECHNOLOGY CO., LTD has been officially admitted as a BLUE Member of the Health Tourism Development Center of Islamic Countries (HTDC)! 🌍

We’re delighted to announce that MedTourChina has officially signed a Framework Strategic Cooperation Agreement with Healtra, a doctor-led healthcare cooperation. This partnership marks the beginning of a new phase of collaboration between China and the GCC region, focusing on knowledge exchange, medical coordination, and healthcare innovation.